{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:03:23Z","timestamp":1773723803398,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejogrb.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T03:34:27Z","timestamp":1712460867000},"page":"106-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes"],"prefix":"10.1016","volume":"297","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0373-9500","authenticated-orcid":false,"given":"Minna","family":"Kanervo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarimari","family":"Tupola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeva","family":"Nikkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Rantakari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Kahila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2024.04.003_b0005","unstructured":"ACOG Committee Opinion. Opioid Use and Opioid Use Disorder in Pregnancy. 2017 Aug;(711):14."},{"issue":"22","key":"10.1016\/j.ejogrb.2024.04.003_b0010","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa2203318","article-title":"Buprenorphine versus methadone for opioid use disorder in pregnancy","volume":"387","author":"Suarez","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.04.003_b0015","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-050279","article-title":"Opioid use disorder and perinatal outcomes","volume":"148","author":"Piske","year":"2021","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.04.003_b0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/AOG.0000000000000640","article-title":"Buprenorphine and naloxone compared with methadone treatment in pregnancy","volume":"125","author":"Wiegand","year":"2015","journal-title":"Obstet Gynecol [Internet]"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.04.003_b0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/ADM.0000000000000099","article-title":"The effect of methadone dose regimen on neonatal abstinence syndrome","volume":"9","author":"McCarthy","year":"2015","journal-title":"J Addict Med [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S155843","article-title":"Depot buprenorphine injection in the management of opioid use disorder: from development to implementation","volume":"10","author":"Ling","year":"2019","journal-title":"Subst Abuse Rehabil [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0035","unstructured":"Product Information, Sublocade. Indivior Pharmaceuticals, July 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209819s000lbl.pdf."},{"key":"10.1016\/j.ejogrb.2024.04.003_b0040","article-title":"Impact of alcohol exposure on neural development and network formation in human cortical organoids","author":"Adams","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0045","unstructured":"European Medicines Agency. Annex to the European Commission guideline on \u2018Excipients in the labelling and package leaflet of medicinal products for human use\u2019 (SANTE-2017-11668) Excipients and information for the package leaflet. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human_en.pdf."},{"issue":"2","key":"10.1016\/j.ejogrb.2024.04.003_b0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/AOG.0000000000004270","article-title":"Subcutaneous buprenorphine extended-release use among pregnant and postpartum women","volume":"137","author":"Bernstein","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0055","article-title":"Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations","volume":"93","author":"Winhusen","year":"2020","journal-title":"Contemp Clin Trials [Internet]"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.04.003_b0060","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/AOG.0000000000004126","article-title":"Subcutaneous buprenorphine extended-release use among pregnant and postpartum women","volume":"136","author":"Cleary","year":"2020","journal-title":"Obstet Gynecol [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0065","doi-asserted-by":"crossref","first-page":"e3127676","DOI":"10.1155\/2020\/3127676","article-title":"Subcutaneous extended-release buprenorphine use in pregnancy","volume":"2020","author":"Towers","year":"2020","journal-title":"Case Rep Obstet Gynecol [Internet]"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.04.003_b0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.14740\/jcgo919","article-title":"What to expect with pregnant or postpartum prescribing of extended-release buprenorphine (CAM2038)","volume":"12","author":"Lofwall","year":"2023","journal-title":"J Clin Gynecol Obstet [Internet]"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.04.003_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07853890.2010.515603","article-title":"New Finnish growth references for children and adolescents aged 0 to 20 years: Length\/height-for-age, weight-for-length\/height, and body mass index-for-age","volume":"43","author":"Saari","year":"2011","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.04.003_b0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/aogs.14497","article-title":"Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder","volume":"102","author":"Kanervo","year":"2023","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.04.003_b0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/10550881003684723","article-title":"Addiction in pregnancy","volume":"29","author":"Keegan","year":"2010","journal-title":"J Addict Dis [Internet]"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.04.003_b0090","article-title":"Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis","volume":"2","author":"Link","year":"2020","journal-title":"Am J Obstet Gynecol MFM [Internet]"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.04.003_b0095","article-title":"Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder","volume":"3","author":"Link","year":"2021","journal-title":"Am J Obstet Gynecol MFM [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0100","first-page":"61","article-title":"A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes","volume":"7","author":"Lund","year":"2013","journal-title":"Subst Abuse Res Treat"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","article-title":"Co-occurring substance use and mental disorders among adults with opioid use disorder","volume":"197","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0110","article-title":"Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone","volume":"228","author":"Zhu","year":"2021","journal-title":"Drug Alcohol Depend [Internet]"},{"issue":"1\u20133","key":"10.1016\/j.ejogrb.2024.04.003_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2012.07.001","article-title":"Neonatal outcomes following in utero exposure to methadone or buprenorphine: A National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009","volume":"127","author":"Welle-Strand","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.04.003_b0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ajad.12687","article-title":"Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure","volume":"27","author":"Nguyen","year":"2018","journal-title":"Am J Addict"},{"issue":"12","key":"10.1016\/j.ejogrb.2024.04.003_b0125","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/add.13462","article-title":"Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child","volume":"111","author":"Zedler","year":"2016","journal-title":"Addict Abingdon Engl"},{"issue":"6","key":"10.1016\/j.ejogrb.2024.04.003_b0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajog.2019.07.022","article-title":"Opioids affect the fetal brain: Reframing the detoxification debate","volume":"221","author":"Caritis","year":"2019","journal-title":"Am J Obstet Gynecol [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2147\/CLEP.S327766","article-title":"Maternal smoking during pregnancy and offspring head growth in comparison to height and weight growth up to 6 years of age: A longitudinal study","volume":"13","author":"Karvonen","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.04.003_b0140","doi-asserted-by":"crossref","first-page":"e0150370","DOI":"10.1371\/journal.pone.0150370","article-title":"Relationships between head circumference, brain volume and cognition in children with prenatal alcohol exposure","volume":"11","author":"Treit","year":"2016","journal-title":"PLoS One [Internet]"},{"key":"10.1016\/j.ejogrb.2024.04.003_b0145","unstructured":"Kanervo M, Luoto L, Tupola S, Nikkola E, Kahila H, Rantakari K. Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatr [Internet]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/apa.17198."},{"key":"10.1016\/j.ejogrb.2024.04.003_b0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2017.11.010","article-title":"Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use","volume":"183","author":"Metz","year":"2018","journal-title":"Drug Alcohol Depend [Internet]"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211524001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211524001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:42:12Z","timestamp":1762285332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211524001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0301211524001702"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2024.04.003","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}